PVLA — Palvella Therapeutics, Inc. Stock Price, Chart & AI Report

Positive Feb 26, 2026 • 00:57 UTC GlobeNewswire Inc. • Not Specified

Palvella Therapeutics Announces Pricing of Upsized Public Offering

Palvella Therapeutics priced an upsized public offering of 1.6 million shares at $125 per share, raising $200 million in gross proceeds before underwriting costs. The clinical-stage biopharmaceutical company plans to use the funds to support development of its QTORIN rapamycin and QTORIN pitavastatin programs for rare skin diseases and vascular malformations. The offering is expected to close on February 27, 2026.

PVLA public offering biopharmaceutical rare skin diseases vascular malformations QTORIN platform clinical-stage capital raise

Sentiment note

The company successfully completed an upsized public offering at $125 per share, raising $200 million to fund development of its pipeline programs. The offering demonstrates investor confidence and provides substantial capital for advancing clinical programs including positive Phase 3 results mentioned in the article.

Positive Feb 23, 2026 • 22:00 UTC GlobeNewswire Inc. • Na

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Palvella Therapeutics announced it will host a conference call on February 24, 2026, at 8:00am ET to discuss topline results from the Phase 3 SELVA clinical trial of QTORIN 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations. The company plans to release results at 6:30am ET prior to the call.

PVLA Phase 3 clinical trial QTORIN rapamycin microcystic lymphatic malformations rare skin diseases vascular malformations FDA approval biopharmaceutical

Sentiment note

The company is advancing a late-stage clinical pipeline with Phase 3 trial results expected, demonstrating progress toward potential FDA approval for treatments addressing unmet medical needs in rare diseases with no current approved therapies. The announcement of topline results from a pivotal Phase 3 trial is typically viewed positively by investors as it represents a significant milestone.

Positive Dec 15, 2025 • 11:00 UTC GlobeNewswire Inc. • Palvella Therapeutics

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

Palvella Therapeutics reported positive Phase 2 trial results for QTORIN™ rapamycin gel in treating cutaneous venous malformations, with 73% of participants showing improvement and no serious adverse events reported.

PVLA rare genetic disease venous malformations clinical trial topical treatment rapamycin

Sentiment note

Achieved statistically significant results in Phase 2 trial, demonstrated potential for first FDA-approved therapy for cutaneous venous malformations, and plans to pursue Breakthrough Therapy Designation

Positive Nov 5, 2025 • 11:00 UTC GlobeNewswire Inc. • Wes Kaupinen

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Palvella Therapeutics introduced a new product candidate, QTORIN™ pitavastatin, targeting disseminated superficial actinic porokeratosis (DSAP), a rare genetic skin disease with no current FDA-approved therapies. The company plans to initiate a Phase 2 clinical trial in the second half of 2026.

PVLA DSAP rare skin disease genetic mutation mevalonate pathway topical treatment

Sentiment note

Company is developing an innovative therapeutic approach for a rare disease with no current treatment options, demonstrating potential for significant medical advancement

Positive Apr 9, 2025 • 08:00 UTC GlobeNewswire Inc. • N/A

Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development

Ebenbuild's digital twin technology Twinhale was used in a study published in Nature Communications, demonstrating the potential of inhaled therapeutics for treating idiopathic pulmonary fibrosis (IPF). The simulations revealed how the novel inhaled Anticalin® protein PRS-220 can effectively target diseased lung tissue, paving the way for more efficient therapies for IPF patients.

PVLA Ebenbuild Twinhale idiopathic pulmonary fibrosis PRS-220 Anticalin Pieris Pharmaceuticals Pavella Therapeutics

Sentiment note

Pavella Therapeutics, Inc. (formerly Pieris Pharmaceuticals) developed the novel inhaled Anticalin® protein PRS-220, which was shown to achieve effective penetration and coverage in fibrotic lung tissue through the use of Ebenbuild's digital twin technology.